The effect of nintedanib on lung functions and survival in
idiopathic pulmonary fibrosis: real-life analysis of the Czech
EMPIRE registry

J 2023

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

STEFANIKOVA, Marianna, Martina DOUBKOVÁ, Petra OVESNÁ, Martina STERCLOVA, Ladislav LACINA et. al.

Basic information

Original name

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

Authors

STEFANIKOVA, Marianna (203 Czech Republic, guarantor), Martina DOUBKOVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution), Martina STERCLOVA (203 Czech Republic), Ladislav LACINA (203 Czech Republic), Monika ZURKOVA (203 Czech Republic), Martina PLACKOVA (203 Czech Republic), Vladimir BARTOS (203 Czech Republic), Ivana JANICKOVA (203 Czech Republic), Radka BITTENGLOVA (203 Czech Republic), Jan ANTON (203 Czech Republic), Lubica SÝKOROVÁ (703 Slovakia, belonging to the institution), Vladimira LOSTAKOVA (203 Czech Republic), Pavlina MUSILOVA (203 Czech Republic), Hana SULDOVA (203 Czech Republic), Radka MOKOSOVA (203 Czech Republic), Jurij DIDYK (203 Czech Republic), Lenka SISAKOVA (203 Czech Republic), Pavlina LISA (203 Czech Republic), Jaroslav LNENICKA (203 Czech Republic), Hana DARICKOVA (203 Czech Republic), Daniel DOLEZEL (203 Czech Republic), Jana PSIKALOVA (203 Czech Republic), Richard TYL (203 Czech Republic), Renata KRALOVA (203 Czech Republic) and Martina KOZIAR VASAKOVA (203 Czech Republic)

Edition

BMC Pulmonary Medicine, London, BMC, 2023, 1471-2466

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30203 Respiratory systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.100 in 2022

RIV identification code

RIV/00216224:14110/23:00131022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s12890-023-02450-3

UT WoS

000981017500001

Keywords in English

Idiopathic pulmonary fibrosis; Nintedanib; Lung function decline; Overall survival

Abstract

V originále

IntroductionThe antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry.Patients/methodsData of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated.ResultsDuring 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN).ConclusionOur real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.

Citovat

STEFANIKOVA, Marianna, Martina DOUBKOVÁ, Petra OVESNÁ, Martina STERCLOVA, Ladislav LACINA, Monika ZURKOVA, Martina PLACKOVA, Vladimir BARTOS, Ivana JANICKOVA, Radka BITTENGLOVA, Jan ANTON, Lubica SÝKOROVÁ, Vladimira LOSTAKOVA, Pavlina MUSILOVA, Hana SULDOVA, Radka MOKOSOVA, Jurij DIDYK, Lenka SISAKOVA, Pavlina LISA, Jaroslav LNENICKA, Hana DARICKOVA, Daniel DOLEZEL, Jana PSIKALOVA, Richard TYL, Renata KRALOVA and Martina KOZIAR VASAKOVA. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry. BMC Pulmonary Medicine. London: BMC, 2023, vol. 23, No 1, p. 1-9. ISSN 1471-2466. Available from: https://dx.doi.org/10.1186/s12890-023-02450-3.

@article{2292980,
   author = {Stefanikova, Marianna and Doubková, Martina and Ovesná, Petra and Sterclova, Martina and Lacina, Ladislav and Zurkova, Monika and Plackova, Martina and Bartos, Vladimir and Janickova, Ivana and Bittenglova, Radka and Anton, Jan and Sýkorová, Lubica and Lostakova, Vladimira and Musilova, Pavlina and Suldova, Hana and Mokosova, Radka and Didyk, Jurij and Sisakova, Lenka and Lisa, Pavlina and Lnenicka, Jaroslav and Darickova, Hana and Dolezel, Daniel and Psikalova, Jana and Tyl, Richard and Kralova, Renata and Koziar Vasakova, Martina},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s12890-023-02450-3},
   keywords = {Idiopathic pulmonary fibrosis; Nintedanib; Lung function decline; Overall survival},
   language = {eng},
   issn = {1471-2466},
   journal = {BMC Pulmonary Medicine},
   title = {The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry},
   url = {https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02450-3},
   volume = {23},
   year = {2023}
}

TY  - JOUR
ID  - 2292980
AU  - Stefanikova, Marianna - Doubková, Martina - Ovesná, Petra - Sterclova, Martina - Lacina, Ladislav - Zurkova, Monika - Plackova, Martina - Bartos, Vladimir - Janickova, Ivana - Bittenglova, Radka - Anton, Jan - Sýkorová, Lubica - Lostakova, Vladimira - Musilova, Pavlina - Suldova, Hana - Mokosova, Radka - Didyk, Jurij - Sisakova, Lenka - Lisa, Pavlina - Lnenicka, Jaroslav - Darickova, Hana - Dolezel, Daniel - Psikalova, Jana - Tyl, Richard - Kralova, Renata - Koziar Vasakova, Martina
PY  - 2023
TI  - The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
JF  - BMC Pulmonary Medicine
VL  - 23
IS  - 1
SP  - 1-9
EP  - 1-9
PB  - BMC
SN  - 14712466
KW  - Idiopathic pulmonary fibrosis
KW  - Nintedanib
KW  - Lung function decline
KW  - Overall survival
UR  - https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02450-3
N2  - IntroductionThe antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry.Patients/methodsData of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated.ResultsDuring 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN).ConclusionOur real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.
ER  -

STEFANIKOVA, Marianna, Martina DOUBKOVÁ, Petra OVESNÁ, Martina STERCLOVA, Ladislav LACINA, Monika ZURKOVA, Martina PLACKOVA, Vladimir BARTOS, Ivana JANICKOVA, Radka BITTENGLOVA, Jan ANTON, Lubica SÝKOROVÁ, Vladimira LOSTAKOVA, Pavlina MUSILOVA, Hana SULDOVA, Radka MOKOSOVA, Jurij DIDYK, Lenka SISAKOVA, Pavlina LISA, Jaroslav LNENICKA, Hana DARICKOVA, Daniel DOLEZEL, Jana PSIKALOVA, Richard TYL, Renata KRALOVA and Martina KOZIAR VASAKOVA. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry. \textit{BMC Pulmonary Medicine}. London: BMC, 2023, vol.~23, No~1, p.~1-9. ISSN~1471-2466. Available from: https://dx.doi.org/10.1186/s12890-023-02450-3.

Detailed Information on Publication Record